Patients in England and Wales with cardiomyopathy caused by the disorder ATTR amyloidosis will soon be able to access treatment with Alnylam's gene-silencing drug Amvuttra. The ruling by reimbursement ...

Alnylam is riding high today after reporting its RNAi drug vutrisiran showed across-the-board efficacy in cardiomyopathy associated with transthyretin-mediated amyloidosis (ATTR), setting up ...

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a serious and debilitating heart condition that may require a collaborative team of experts. ATTR-CM not only affects the heart, it also often impacts ...

The same abnormal proteins that can build up in your heart when you have transthyretin cardiac amyloidosis (ATTR-CM) can also leave deposits in your spine, resulting in spinal stenosis. The symptoms ...

The outlook for transthyretin amyloidosis (ATTR amyloidosis) depends on factors such as your type, affected organs, and how early you start treatment. Average survival rates differ by type: familial ...

TTR Stabilizers Gene Silencers Which Is Right for You? If youve been diagnosed with transthyretin cardiac amyloidosis (ATTR-CM), you may be debating between two treatments: transthyretin (TTR) ...

Amyloidosis occurs when a protein called amyloid builds up in organs such as the heart, kidneys, liver, nerves, and digestive system. Deposits may be body-wide or localized and can lead to organ ...